You can buy or sell OpGen and other stocks, options, ETFs, and crypto commission-free!
OpGen, Inc. engages in the development of molecular information products and services for global healthcare settings. It helps to guide clinicians with more rapid and actionable information about life threatening infections, improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms (MDROs). Read More The company was founded on January 22, 2001 and is headquartered in Gaithersburg, MD.
52 Week High
52 Week Low
Seeking AlphaMay 14
OpGen, Inc. CEO Evan Jones on Q1 2019 Results - Earnings Call Transcript
OpGen, Inc. (NASDAQ:OPGN) Q1 2019 Earnings Conference Call May 14, 2019 4:30 PM ET Company Participants Evan Jones - Chairman and Chief Executive Officer Timothy Dec - Chief Financial Officer Conference Call Participants Edward Marks - H.C. Wainwright & Co. Nathan Weinstein - Aegis Capital Corporation Maxim Jacobs - Edison Group Benjamin Haynor - Alliance Global Partners Anthony Polak - Aegis Capital Corp. John Power - Redwood MicroCap Fund Inc. Operator Welcome to the OpGen First Quarter 2019 C...
Seeking AlphaMay 14
OpGen up 10% premarket on U.S. application for molecular test
Thinly traded nano cap OpGen (NASDAQ:OPGN) is up 10% premarket on light volume on the heels of its 501(k) submission to the FDA seeking clearance for its Acuitas AMR Gene Panel test for the detection of antimicrobial resistance genes in bacterial isolates.
Yahoo FinanceMay 7
Will OpGen, Inc. (OPGN) Report Negative Q1 Earnings? What You Should Know
The market expects OpGen, Inc. (OPGN) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2019. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates. The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they...
-$0.31 per share
-$0.36 per share